主页 > 医学动态 >
【medical-news】心衰患者服用美托洛尔比服用卡维
New Onset Diabetes More Likely With Metoprolol Than With Carvedilol in Heart Failure
NEW YORK (Reuters Health) Aug 06 - New onset diabetes in patients with chronic heart failure is more likely to develop with metoprolol than with carvedilol, according to findings published in the August issue of Heart.
Previous studies have shown carvedilol to have a more favorable effect on glucose metabolism than other beta blockers have, the authors explain.
Dr. Christian Torp-Pedersen from Bispebjerg University Hospital, Copenhagen, Denmark and colleagues in the Carvedilol or Metoprolol European Trial (COMET) investigated whether carvedilol was associated with a different incidence of new onset diabetes compared with metoprolol in more than 3000 patients with chronic heart failure.
Patients taking carvedilol were 22% less likely to develop new onset diabetes than patients taking metoprolol, the authors report. New onset diabetes was diagnosed in 119 out of 1151 (10.3%) of patients taking carvedilol, versus 145 out of 1147 (12.6%) of patients taking metoprolol.
Diabetes-related adverse events were also 22% less likely to occur among carvedilol patients: 122 events versus 149 events.
Metoprolol remained an independent predictor of new onset diabetes in a multivariable model that included body mass index, hypertension, functional class, and other factors.
Patients treated with metoprolol also showed a significant trend for an increase in random blood glucose levels over the course of the trial, the investigators write.
Treatment with carvedilol was associated with a nonsignificant risk reduction for mortality compared with metoprolol for diabetic and nondiabetic patients, the researchers note.
In a multivariate analysis, however, treatment with metoprolol and a diagnosis of diabetes were independently associated with greater all-cause mortality.
"This study demonstrates that treatment with carvedilol is associated with less development of new onset diabetes in patients with heart failure compared with treatment with metoprolol tartrate," the authors conclude. "The study further demonstrates that not only is the prevalence of diabetes high in patients with heart failure but also the incidence is high, amounting to 10-15% over 5 years." 我认领，24小时内完成。 我是新手，请大虾们多指正，多鼓励！
New Onset Diabetes More Likely With Metoprolol Than With Carvedilol in Heart Failure
心衰患者服用美托洛尔比服用卡维地洛更易新发糖尿病
NEW YORK (Reuters Health) Aug 06 - New onset diabetes in patients with chronic heart failure is more likely to develop with metoprolol than with carvedilol, according to findings published in the August issue of Heart.
纽约(路透社健康)8月6日-8月版《心脏》杂志报道:慢性心衰患者服用美托洛尔比服用卡维地洛更易诱发糖尿病.
Previous studies have shown carvedilol to have a more favorable effect on glucose metabolism than other beta blockers have, the authors explain.
文章称，前期研究表明卡维地洛对糖代谢的作用优于其它的β-R阻滞剂。
Dr. Christian Torp-Pedersen from Bispebjerg University Hospital, Copenhagen, Denmark and colleagues in the Carvedilol or Metoprolol European Trial (COMET) investigated whether carvedilol was associated with a different incidence of new onset diabetes compared with metoprolol in more than 3000 patients with chronic heart failure.
丹麦哥本哈根克Bispebjerg大学医院的里斯蒂娜.托普.彼德森博士及其参加COMET的同事，在3000多慢性心衰患者中，对卡维地洛是否与异于美托洛尔的糖尿病新发率相关性进行了研究。
Patients taking carvedilol were 22% less likely to develop new onset diabetes than patients taking metoprolol, the authors report. New onset diabetes was diagnosed in 119 out of 1151 (10.3%) of patients taking carvedilol, versus 145 out of 1147 (12.6%) of patients taking metoprolol.
据报道，服用卡维地洛的患者新发糖尿病的可能性比服用美托洛尔者低22%。服用卡维地洛的1151位患者中诊断新发糖尿病者119人（占10.3%），服用美托洛尔的1147位患者中诊断新发糖尿病者145人（占12.6%）。
Diabetes-related adverse events were also 22% less likely to occur among carvedilol patients: 122 events versus 149 events.
服用卡维地洛患者糖尿病相关不良事件的发生率比服用美托洛尔者低22%，分别为122例和149例。
Metoprolol remained an independent predictor of new onset diabetes in a multivariable model that included body mass index, hypertension, functional class, and other factors.
在包括体重指数、高血压、功能级别以及其他因素的多变量模型中，美托洛尔还是新发糖尿病的一个独立预测因素。
Patients treated with metoprolol also showed a significant trend for an increase in random blood glucose levels over the course of the trial, the investigators write.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-04 05:12
医学,生命科学网